Episode 2 of Demystifying NMO by The Sumaira Foundation (TSF) for NMO and Connor B Judge Foundation (CBFJ) focuses on NMO Treatments: Acute vs Maintenance. Follow along to hear a candid conversation between Connor, of the CBJF and NMO patient, and his sister Chelsey, also scientific advisor with the CBJF. In their discussion, they talk about the differences in treatments to manage an active relapse versus to help prevent relapse. Glossary of Terms UsedAQP4: aquaporin-4; a water channel protein found in the CNS; antibodies can be made against this in NMOSD patientsB-cell: a white blood cell that is a key component of the adaptive immune system and makes antibodiesImmunosuppressant: a medication that reduces/supresses the function of some immune system component MOG: myelin-oligodendrocyte glycoprotein; a myelin protein; antibodies can be made against this in some NMOSD patientsRelapse: clinical disease activity/clinical worsening

Episode 3: Gratitude through NMO

Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein antibody disease (MOGAD) are neurological autoimmune diseases that cause blindness and paralysis. While NMOSD and MOGAD are rare diseases, autoimmune diseases are common, and so is finding scientific and medical jargon tricky to understand. In this podcast, The Sumaira Foundation works to simplify the science associated with NMOSD, MOGAD, and related neuro-immune disorders, bringing together patients and experts.